Yong He
18PUBLICATIONS
40CO-AUTHORS
Get your video featured.
Publish with JoVEGet your video featured.
Publish with JoVE
Publications (18)
Sort by Publication Date:
|Apr 14, 2025
ATF3 Within the Interferon Signaling Pathway: A Potential Biomarker for Predicting Pathological Response to Neoadjuvant Chemoimmunotherapy.Chao He, Rui Han, Taiming Zhang
|Feb 19, 2025
Multieffect Specific Nanovesicles for Homing Resistant Tumors and Overcoming Osimertinib-Acquired Resistance in NSCLC.Yuanyao Dou, Yihui Liu, Rui Han
|Dec 31, 2024
Efficacy and Safety of Chemotherapy or EGFR-TKIs as First-Line Therapy in NSCLC Patients Harboring Non-Ex 20 Ins Uncommon EGFR Mutations: A Retrospective Study in China.Chen Liao, Li Bai, Tingting He
|Oct 15, 2024
Clinical Management in NSCLC Patients With EGFR Mutation After Osimertinib Progression With Unknown Resistance Mechanisms.Xin Liao, Tingting He, Xiong Wan
|Jun 22, 2024
Understanding the dynamics of TKI-induced changes in the tumor immune microenvironment for improved therapeutic effect.Conghua Lu, Ziyuan Gao, Di Wu
|Jan 14, 2024
Rechallenge of immune checkpoint inhibitors in advanced non-small cell lung cancer.Gen Lin, Zhijie Wang, Qian Chu
Pageof 3
